Impact GLP-1 Agonists Following Bariatric

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 150 participants.

Also called NCT06132477

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
University of Missouri-Columbia (from the registry)
Registry
  • NCT NCT06132477
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06132477. Randomized; no masking; primary purpose treatment. Start 2024-02-01 (actual); primary completion 2028-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Impact GLP-1 Agonists Following Bariatric
Condition
Morbid Obesity
Condition
Diabetes Mellitus
Condition
Hypertension
Condition
Obstructive Sleep Apnea of Adult
Intervention (Drug)
GLP-1 receptor agonist
Lead sponsor
University of Missouri-Columbia (class: other)
Collaborator
American Society for Metabolic and Bariatric Surgery (class: other)

Record details

Record id
cardio:ct-nct06132477
Content hash
84307975ea6459f49f32f1bc4634a6af7ae7a4b4841514390ed2980f7b71f81d